Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Related to this article
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
2
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
3
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
4
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
5